Ardelyx, Inc. Sustainability Profile
Ardelyx, Inc., a biopharmaceutical company headquartered in the United States, is dedicated to developing innovative therapies for patients with gastrointestinal and renal diseases. Founded in 2007, Ardelyx has made significant strides in the industry, particularly with its focus on unique mechanisms of action that address unmet medical needs. The company’s flagship product, tenapanor, is designed to treat conditions such as irritable bowel syndrome with constipation (IBS-C) and hyperphosphataemia in patients with chronic kidney disease. Ardelyx's commitment to scientific excellence and patient-centric solutions has positioned it as a notable player in the biopharmaceutical landscape. With a robust pipeline and a focus on advancing healthcare, Ardelyx continues to make impactful contributions to the industry.
DitchCarbon Score
How does Ardelyx, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ardelyx, Inc.'s score of 25 is lower than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ardelyx, Inc.'s reported carbon emissions
Ardelyx, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Ardelyx may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. As a result, the company does not appear to be actively participating in industry-standard climate frameworks such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). Without emissions data or reduction commitments, Ardelyx's climate strategy remains unclear within the broader context of corporate sustainability efforts.
How Carbon Intensive is Ardelyx, Inc.'s Industry?
How Carbon Intensive is Ardelyx, Inc.'s Location?
Ardelyx, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Ardelyx, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
